00421nas a2200097   4500000000100000008004100001100001500042245024400057300001400301490000800315       2020                            d1 aK Mahaffey00aEvaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial  a407 - 4100 v141